TalkON
SaaS System for Helping Improve Speech Therapy Outcomes
Company Overview
Snapshot
Founded in January 2018 by Leetal Tisman, Hila Bornstein, and Michael Schiller, TalkON operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing its AI-powered SaaS system for speech therapy.
Business overview
TalkON develops an AI-driven SaaS system designed to create personalized speech therapy programs for children. This technology provides parents with tools for home practice, ensuring continuity in therapy, while enabling therapists to make data-driven decisions through objective measurements. The company's solution aims to enhance the efficiency of speech therapy, shorten treatment durations, and reduce frustration, ultimately making therapy more accessible and cost-effective for families and institutions. TalkON operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Digital Therapeutics, leveraging artificial intelligence and machine learning.
Log in to access full profile ›Company Intelligence Q&A
- What is TalkON's primary focus?
- TalkON's primary focus is on developing an AI-based SaaS system to improve speech therapy outcomes for children by providing tailored programs and tools for home practice.
- When was TalkON founded and by whom?
- TalkON was founded in January 2018 by co-founders Leetal Tisman, Hila Bornstein, and Michael Schiller.
- What technology does TalkON utilize?
- TalkON's system is based on artificial intelligence and machine learning to build personalized speech therapy programs and provide objective measurements for therapists.
- What problem does TalkON aim to solve?
- TalkON aims to make speech therapy more efficient, accessible, and cost-effective by shortening therapy periods and preventing frustration and future difficulties for children and their families.
- What is the current product stage of TalkON?
- TalkON's product is currently in the Beta stage, indicating it is undergoing testing and refinement before a full public release.